Copeptin Biomarker Assay for Early Preeclampsia Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing preeclampsia are inadequate due to poor understanding of its pathogenesis, leading to elusive preventative and therapeutic modalities, and existing diagnostic tools lack effectiveness in early prediction.
Innovation Solution
Measuring copeptin levels in a sample collected during the first trimester using an antibody detection assay, combined with Doppler velocimetry measurements, to predict the likelihood of preeclampsia, with a kit including a test strip or ELISA for accurate detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for preeclampsia, then current standards are maintained, but early prediction capability is insufficient and pathogenesis understanding is poor
Solution Approach 1:
The patent measures copeptin levels during the first trimester of pregnancy to predict the risk of developing preeclampsia before severe symptoms appear. This preliminary measurement allows for early identification of at-risk pregnancies and enables timely intervention strategies, improving early prediction capability while the pathogenesis mechanism remains under investigation
Solution Approach 2:
The patent uses copeptin as an intermediary biomarker to assess preeclampsia risk. Copeptin serves as a stable surrogate marker that can be measured in urine or plasma during the first trimester, providing reliable prediction data without requiring direct measurement of the complex pathophysiological processes underlying preeclampsia
2Measurement precision
If copeptin measurement is performed during first trimester, then early prediction accuracy improves, but diagnostic timing constraints are created
Solution Approach 1:
The patent performs copeptin measurement during the first trimester, which is the optimal early window for prediction. By conducting the test at this specific time point, the patent captures baseline hormonal levels that predict future preeclampsia risk, maximizing prediction accuracy while working within the constrained early diagnostic timeline
3Reliability
If multiple measurement methods are used (urine, blood, serum, plasma), then detection reliability improves, but test complexity increases
Solution Approach 1:
The patent specifies that copeptin measurement can be performed using multiple sample types including urine, blood, serum, or plasma. This multi-functionality allows the same diagnostic approach to be adapted to different clinical settings and patient preferences, improving detection reliability through option flexibility without requiring entirely different test systems
Solution Approach 2:
Copeptin serves as a universal intermediary marker that can be detected across multiple sample types. This property allows the patent to maintain consistent diagnostic reliability whether measuring from urine (first void) or blood/serum/plasma samples, simplifying the overall test approach while providing flexible collection options
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Early prediction of preeclampsia allows for timely intervention, potentially reducing maternal and fetal morbidity and mortality by identifying at-risk pregnancies before severe symptoms develop.
Implementation Method 1
measuring differences in copeptin levels in a sample collected from a subject during the first trimester of pregnancy compared to a control using an antibody detection assay
Implementation Method 2
the method further comprising taking Doppler velocimetry measurements on at least one of the subject's uterine and umbilical arteries
Data Source
Figure 1~2C
Figure 3A~3D
Figure 4A~4F
AI summary
Assays, kits, methods, and devices for diagnosing or predicting the likelihood of occurrence preeclampsia in a subject are disclosed.